1. Maltais F, et al. Eur Respir J 2010; 36:1014s;
2. Buhl R, et al. Eur Respir J 2015; 45:969–979;
3. Buhl R, et al. Am J Respir Crit Care Med 2019; 199:A7098;
4. Cazzola M, et al. CHEST 2018; 154:746–748;
5. Barrecheguren M, et al. CHEST 2018; 154:749–751.

This study was supported by Boehringer Ingelheim. Olive Denneny, MSc, at MediTech Media provided editorial assistance in the development of this poster, funded by Boehringer Ingelheim. The authors would like to thank all the patients for participating in these trials, and they also extend their thanks to the investigators.

KFR has received personal fees from Boehringer Ingelheim, AstraZeneca, Novartis and Chiesi, and grants from Boehringer Ingelheim, AstraZeneca and Takeda. JC has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Grifols, Insmed, Novartis and Zambon, grants from Gilead, and personal fees from Napp. MM has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Gebro Pharma, GSK, Grifols, MedImmune, Menarini, Mereo BioPharma, Novartis, Sandoz and Teva. JK has received grants and personal fees from AstraZeneca, Boehringer Ingelheim and GSK, grants from Chiesi, and personal fees from Mundi Pharma and Teva. IT has received grants and personal fees from GSK, grants from ELPEN, and personal fees from Boehringer Ingelheim, Menarini and Novartis. AdlH and WX are employees of Boehringer Ingelheim. JW has received grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Johnson and Johnson, and Novartis, and meeting expenses from AstraZeneca, Boehringer Ingelheim, GSK and Novartis. DS reports personal fees from Apellis, Cipla, Genentech, Peptinnovate and Skyepharma, and grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Theravance and Verona. GTF has received grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Pearl Therapeutics, Sunovion and Theravance, and personal fees from Circassia, Innoviva, Mylan and Verona.